Fresh From US FDA's Chief Counsel Office, Beth Weinman Talks Qui Tam And Compliance
Beth Weinman, a former enforcement lawyer in US FDA’s Office of Chief Counsel, recently joined the life sciences and FDA regulatory practice at Ropes & Gray. She spoke with Medtech Insight about whistleblower suits and FDA enforcement priorities.
You may also be interested in...
A day after 23andMe gained US FDA go-ahead for a DTC genetic test service to inform patients about their ability to metabolize medications, the agency issued a safety communication, paired with a joint statement from device- and drug-center heads, warning consumers against trusting genetic tests that have not been vetted by FDA.
Radiofrequencies from the incontinence-sensing devices may interfere with other medical equipment in a hospital setting.
The former diagnostics company executive was convicted in January on four counts of fraud.